Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
Provided By GlobeNewswire
Last update: Dec 11, 2025
TN-401 was Well Tolerated at 3E13 vg/kg dose
Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8
Read more at globenewswire.com0.85
-0.51 (-37.5%)
Find more stocks in the Stock Screener
TNYA Latest News and Analysis
